RxDoctor Payments Data

Jessica Lunsford, APRN

Family · Sheridan, ARNPI 1083371686

Payments from drug & device makers

$633in general payments, 2019–2025

Across 38 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$120
  • Novo Nordisk$104
  • AbbVie$74
  • GSK$62
  • AstraZeneca$44
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$31
  • plus $197 from 10 others

What the payments were for

  • Food & beverage$633100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$633 in reported general payments places this provider in the 60th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$9,070
Medicare patients
84
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$18,315
LinzessLinaclotide19$9,434
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,054
Albuterol Sulfate HfaAlbuterol Sulfate129$3,774
Ventolin HfaAlbuterol Sulfate20$1,125
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst62$1,055
Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort15$755
Cephalexin94$735
Azithromycin122$627
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort12$608
Gabapentin71$596
Doxycycline Hyclate60$449
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$422
Hydroxyzine Hcl36$362
Baclofen35$336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$104$18,31518 claims
AbbVieLinzess$74$9,43419 claims
GSKTrelegy Ellipta$62$8,05412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,103 family providers in Arkansas.

Other family in Sheridan

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →